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Abstract
Purpose—Breast cancer is the leading cause of cancer mortality in women worldwide. With 
medical advances, metastatic breast cancer (MBC) patients often live for years with many 
symptoms that interfere with activities. However, there is a paucity of efficacious interventions to 
address symptom-related suffering and functional interference. Thus, this study examined the 
feasibility and preliminary efficacy of telephone-based acceptance and commitment therapy 
(ACT) for symptom interference with functioning in MBC patients.
Methods—Symptomatic MBC patients (N=47) were randomly assigned to six telephone sessions 
of ACT or six telephone sessions of education/support. Patients completed measures of symptom 
interference and measures assessing the severity of pain, fatigue, sleep disturbance, depressive 
symptoms, and anxiety.
Results—The eligibility screening rate (64%) and high retention (83% at 8 weeks post-baseline) 
demonstrated feasibility. When examining within-group change, ACT participants showed 
decreases in symptom interference (i.e., fatigue interference and sleep-related impairment; 
Cohen’s d range=−.23 to −.31) at 8 and 12 weeks post-baseline, whereas education/support 
participants showed minimal change in these outcomes (d range=−.03 to .07). Additionally, at 12 
weeks post-baseline, ACT participants showed moderate decreases in fatigue and sleep 
disturbance (both ds=−.43), whereas education/support participants showed small decreases in 
these outcomes (ds=−.24 and −.18 for fatigue and sleep disturbance, respectively). Both the ACT 
and education/support groups showed reductions in depressive symptoms (ds=−.27 and −.28) at 12 
weeks post-baseline. Group differences in all outcomes were not statistically significant.
Conclusions—ACT shows feasibility and promise in improving fatigue and sleep-related 
outcomes in MBC patients and warrants further investigation.
Keywords
metastatic breast cancer; acceptance and commitment therapy; psychosocial interventions; 
symptom interference; fatigue; sleep
Introduction
With an estimated 522,000 deaths in 2012 alone, breast cancer is the leading cause of cancer 
death in women worldwide [1]. While there are medical advances to increase the longevity 
of metastatic breast cancer (MBC) patients, important symptoms persist that are a major 
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source of suffering, impairment, and disability [2–8]. The most prevalent, persistent, and 
disabling symptoms in MBC patients include pain, fatigue, sleep disturbance, depression, 
and anxiety [2,9–12]. Research suggests that over half of MBC patients have significant 
levels of pain or fatigue, which often co-occur with sleep problems [2,5,13]. Indeed, over 
60% report at least one type of sleep disturbance (e.g., waking in the night) [11], and 
worsening depression has predicted increased sleep disturbance over time [12]. Depression 
and anxiety also affect a substantial number of MBC patients, with 36% having one or both 
of these disorders [9].
Psychological and physical symptoms have been found to interfere with daily activities of 
MBC patients [5,6]. In a cross-sectional study, greater global symptom severity and 
interference showed moderate to strong correlations with decreased work productivity and 
activity engagement in this population [5]. Another study of MBC patients found that 
increases in depressive symptoms predicted greater social and recreational activity 
disruption during a 3-month period [6].
To date, non-pharmacologic interventions to reduce symptoms and distress in MBC patients 
have shown limited evidence of efficacy [14,15]. A 2013 Cochrane meta-analysis of 10 
randomized controlled trials (RCTs) found that psychosocial interventions for MBC 
patients, most of which were group cognitive-behavioral or supportive expressive 
psychotherapy, only produced small, short-term improvement in pain and distress [14]. 
Similar conclusions were made in a recent systematic review of psychosocial interventions 
for MBC patients that included five additional RCTs [15]. Novel intervention approaches are 
needed to significantly decrease symptom-related suffering and interference with daily 
activities.
One psychosocial intervention that shows potential for reducing symptom-related suffering 
in cancer patients is acceptance and commitment therapy (ACT) [16]. In contrast to 
traditional cognitive-behavioral interventions that focus on symptom reduction and 
modifying maladaptive thoughts [17,18], the goal of ACT is to increase psychological 
flexibility so that unwanted internal experiences (e.g., physical symptoms, feelings, 
thoughts) interfere less with patients’ engagement in meaningful activities [19]. 
Psychological flexibility involves fully experiencing the present moment while engaging in 
actions consistent with personal values [20]. This flexibility is developed through ACT’s six 
core processes – mindfulness, perspective taking, cognitive defusion, acceptance, values 
clarification, and committed action [20] – and has been related to reduced anxiety and 
depressive symptoms and improved well-being in cancer patients [21,22].
ACT is efficacious for decreasing distress and promoting physical well-being and self-
management in patients with medical conditions, such as diabetes and chronic pain [23,24]. 
For example, a systematic review of 10 RCTs of ACT for patients with chronic pain 
concluded that ACT enhances physical functioning and decreases distress when compared to 
control conditions [23]. Recently, ACT has been applied to cancer patients in several pilot 
trials [25]. Additionally, one RCT with late-stage ovarian cancer patients found large 
improvement in distress and quality of life among ACT participants compared to those 
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assigned to cognitive-behavioral therapy [26]. These preliminary findings suggest that ACT 
warrants further study in patients with advanced cancer.
We developed an ACT intervention to reduce symptom interference (i.e., the degree to which 
symptoms interfere with cognition, mood, and activities) among MBC patients. The 
intervention protocol was an adaptation of ACT to cancer symptom management based on 
two manuals [16,27]. The intervention emphasizes mindfulness practice; acceptance of 
thoughts, feelings, and physical symptoms through the use of metaphors and experiential 
exercises; clarification of personal values; and engagement in actions consistent with these 
values. We tailored the intervention to the experiences of MBC patients who often have high 
physical and psychological symptom burden [7] and delivered it via telephone to enhance 
feasibility for patients in rural areas and those with physical impairments.
This pilot trial tested the feasibility and preliminary efficacy of ACT relative to an education/
support condition that controlled for time and attention. We enrolled MBC patients who had 
moderate to severe levels of at least one of five common symptoms (i.e., pain, fatigue, sleep 
disturbance, depressive symptoms, or anxiety). Feasibility was assessed via recruitment, 
retention, and session completion rates. Preliminary efficacy was assessed via ACT’s impact 
on symptom interference (i.e., global symptom interference, pain interference, fatigue 
interference, and sleep-related impairment) compared to the education/support condition. 
Although distress and symptom reduction is not the primary goal of ACT, this intervention 
has led to improvement in mood and symptoms in some trials with medical populations, 
including cancer patients [23–25]. Thus, we compared the two interventions with respect to 
severity of pain, fatigue, sleep disturbance, depressive symptoms, and anxiety. We also 
examined within-group changes relative to baseline for all study outcomes.
Methods
Participants
Eligible patients had been diagnosed with stage IV breast cancer at least 3 weeks prior to 
enrollment and had at least one moderate to severe symptom, defined by T-scores ≥55 (at 
least one-half standard deviation above the population mean) on a 3-item Patient Reported 
Outcomes Measurement Information System (PROMIS) measure of pain severity or 4-item 
PROMIS measures of fatigue, sleep disturbance, depressive symptoms, or anxiety [28,29]. 
Patients were excluded if they 1) had severe cognitive impairment defined as 3 or more 
errors on a six-item cognitive screener [30]; 2) had a self-reported Eastern Cooperative 
Oncology Group (ECOG) score > 2 (able to do little activity) [31,32]; 3) were receiving 
hospice care at the time of enrollment; or 4) lacked English fluency.
Procedures
Participants were recruited from the Indiana University (IU) Simon Cancer Center in 
Indianapolis, IN between March and November 2016. The IU institutional review board 
approved all study procedures. Initial patient eligibility was determined via chart review and 
consultation with the attending oncologist. Letters of invitation and consent forms were 
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mailed to patients approved for contact. Trained research assistants called patients to screen 
for eligibility and obtain informed consent.
Consenting patients completed baseline telephone assessments and were randomly assigned 
to either the ACT or education/support condition. Randomization was performed by a person 
who was not a study interviewer or therapist using a SAS procedure and was stratified by 
patient performance status (self-reported ECOG scores 0 or 1 vs. 2) because this factor 
informs cancer treatment decision-making [33]. Patients completed follow-up telephone 
assessments at 8 and 12 weeks post-baseline and received $25 gift cards for each 
assessment. Trained research assistants administering the assessments were blind to study 
condition.
Measures
Primary and secondary outcomes were assessed with valid self-report measures that have 
been used with cancer patients. Higher scores on each measure indicate greater symptom 
interference or severity. In this study, Cronbach’s alphas across all measures ranged from .74 
to .96.
Primary Outcome—The primary outcome of symptom interference with cognition, mood, 
and activities was assessed with the following measures: 1) 6-item global symptom 
interference subscale of the MD Anderson Symptom Inventory (MDASI) [34]; 2) the 4-item 
PROMIS scale for pain interference [35]; 3) seven interference items from the Fatigue 
Symptom Inventory (FSI) [36]; and 4) the 8-item PROMIS scale for sleep-related 
impairment [37].
Secondary Outcomes—The following measures assessed the severity of physical 
symptoms: 1) the 3-item PROMIS pain intensity measure; 2) the 4-item PROMIS short-form 
fatigue measure; and 3) the 4-item PROMIS short-form sleep disturbance measure [28,29]. 
In addition, depressive and anxiety symptoms were assessed with the 4-item PROMIS short-
form depression measure and 4-item PROMIS short-form anxiety measure, respectively 
[38].
Sociodemographic and Medical Variables—At baseline, patients reported their 
demographics and mental health service use. Patient medical information was collected via 
chart review.
Study Conditions
Patients in both study conditions (ACT and education/support) were asked to complete six 
weekly 50 to 60-minute telephone sessions, which were audiorecorded. Six sessions is 
comparable to the duration of other interventions with this population [15]. The ACT 
condition was delivered by a master’s level social worker with experience in ACT, whereas 
the education/support condition was delivered by a Ph.D. student in clinical psychology with 
experience in psychoeducation. The therapists were trained and supervised by two 
psychologists. Training consisted of didactics and role-plays of treatment sessions detailed 
in manuals. Supervision was weekly. Fidelity checklists were developed for both study 
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conditions, and one of the psychologists randomly selected 18% of audiorecordings to 
review for adherence to the manuals. The average fidelity rating was 99%. Both 
psychologists provided feedback on treatment adherence and quality.
ACT Condition—The ACT intervention incorporated all key processes of the ACT model 
of behavior change, including mindfulness, perspective taking, cognitive defusion, 
acceptance, values clarification, and committed action [20]. The intervention had a particular 
emphasis on developing mindfulness skills, engaging in actions consistent with personal 
values, and responding more effectively to symptoms. Each patient was mailed handouts 
summarizing the topics of each session and a CD with guidance for mindfulness practices. 
Table 1 shows a summary of the intervention components.
During the first session, the patient’s background and strategies for managing symptoms 
were discussed and the concept of mindfulness was introduced. Across the six sessions, 
patients practiced various mindfulness exercises, clarified their values, and set specific 
actions to pursue in alignment with their values. During each session, the therapist assessed 
the patient’s home practice of mindfulness and other skills and ended with a discussion of 
home practice for the week ahead. Although each participant learned the same set of skills, 
in-session and home practices were tailored to their cancer-related experiences and other 
challenges.
Education/support Condition—Similar to other psychosocial intervention trials for 
advanced cancer [39,40], the comparison group was an education/support condition. The 
intervention involves directing patients to resources for practical and health information and 
contact information for psychosocial services. A summary of the education/support 
components is found in Table 1. The sessions included the following topics: orientation to 
the medical center and treatment team; the effects of cancer on quality of life; resources for 
psychosocial support, health information, and financial concerns; and strategies for 
evaluating health information in books, magazines, and websites. Sessions were not tailored 
to each participant, except for the omission of topics that did not apply to the participant. 
Each patient was mailed handouts summarizing the topics for each session and was asked to 
review them at home.
Statistical Analyses
Descriptive statistics were computed to examine feasibility indicators. Baseline comparisons 
of study conditions (Fisher’s exact tests and t-tests) were conducted. Linear mixed-effects 
model analyses (SAS Proc Mixed) were used to assess the preliminary efficacy of ACT, and 
an intent-to-treat framework was implemented. The last observation carried forward method 
was used to address missing data. Models included the baseline value of the outcome as a 
covariate and the main effects of time (8 vs. 12 weeks post-baseline) and study group (ACT 
vs. education/support). Both time and study group were categorical variables in these 
models, which focuses the analysis on mean differences across groups and time. A treatment 
effect is indicated by a significant study group main effect. Two-sided p-values < .05 were 
considered statistically significant. To calculate effect sizes for within-group changes, the 
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means of the differences between baseline and each follow-up were divided by the standard 
deviations of the change.
Results
Feasibility
Of the 158 MBC patients who were approached, 50 consented, 50 declined to participate, 38 
were ineligible, and 20 could not be reached via phone. Primary reasons for declining were 
lack of interest and time constraints. Most ineligible patients did not meet the symptom 
criterion for study entry. Forty-seven of 50 consenting patients completed the baseline 
assessment and were included in the current analyses (Fig. 1). Retention was high, with 
17/23 women in the ACT condition and 22/24 women in the education/support condition 
completing all six sessions. Additionally, 83% (39/47) completed the 8-week follow-up, and 
79% (37/47) completed the 12-week follow-up. Retention rates did not differ by study 
condition.
Participant Characteristics
Table 2 shows participant characteristics by study group and group comparisons at baseline. 
All participants were women and most were Caucasian. Participants had, on average, 
completed some college, and the median annual household income was above $50,000. No 
significant baseline differences on demographic or medical factors were found for patients 
randomized to ACT and education/support conditions, with the exception of radiation 
receipt. Regarding study outcomes at baseline, the ACT group showed higher levels of 
global symptom interference, fatigue interference, sleep-related impairment, and sleep 
disturbance than the education/support group (Table 2).
Patient symptom outcomes at baseline were compared to population norms for PROMIS 
measures. Elevated levels of a symptom outcome were defined as T-scores ≥ 60 (+1 SD). 
Thirty percent of patients had elevated pain interference, and 28% had elevated sleep-related 
impairment. Regarding symptom severity, 2% reported elevated pain, and 19% reported 
elevated sleep disturbance. Fatigue was the most prevalent problem, with 47% reporting 
elevations of this symptom. Regarding psychological symptoms, 19% had elevated 
depressive symptoms and 17% had elevated anxiety.
Preliminary Efficacy
Primary Outcomes—Results of the mixed-effects model analyses revealed no main 
effects of study group for indicators of patient symptom interference (i.e., global symptom 
interference, pain interference, fatigue interference, sleep-related impairment; Table 3). 
There were also no main effects of time, suggesting that primary outcome variables did not 
change on average between 8 and 12 weeks post-baseline.
Effect sizes for the mean change in primary outcomes from baseline to 8 and 12 weeks were 
computed for each study group (Table 4). Regarding change in global symptom interference, 
the ACT group showed small decreases (ds = −.19 and −.14) and the education/support 
group showed small increases (ds = .11 and .20) in this outcome (Fig. 2a). For both study 
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groups, effect sizes for change in pain interference were near zero, with the exception of a 
small decrease for the education/support group (d = −.19) at 8 weeks post-baseline (Fig. 2b). 
Regarding change in fatigue interference and sleep-related impairment, small to moderate 
decreases were found for the ACT group (d range = −.23 to −.31), whereas the education/
support group had effect sizes close to zero at both follow-ups (Fig. 2c and 2d).
Secondary Outcomes—Results of the mixed-effects model analyses revealed no main 
effects of study group on patient symptom severity, including pain, fatigue, depressive 
symptoms, and anxiety (Table 3). However, there was a significant main effect of time on 
pain, indicating that patients in both groups, on average, reported a small increase in pain 
between 8 and 12 week follow-ups.
Effect sizes for mean change in exploratory outcomes from baseline to 8 and 12 weeks were 
also computed for each study group (Table 4). At the 12-week follow-up, the ACT group 
showed moderate decreases in fatigue and sleep disturbance (both ds = −.43), whereas the 
education/support group showed small decreases in these outcomes (ds = −.24 and −.18 for 
fatigue and sleep disturbance, respectively). Also at 12-week follow-up, reductions in 
depressive symptoms were nearly identical for both groups (ds = −.27 for ACT and −.28 for 
education/support), and small reductions in anxiety were found (ds = −.18 for ACT and −.08 
for education/support). Little change in pain intensity also was observed at 12-week follow-
up (ds = −.14 for ACT and .03 for education/support).
Discussion
This study examined the feasibility and preliminary efficacy of a 6-session, telephone-based 
ACT intervention for symptom interference in MBC patients. The intervention showed 
strong evidence of feasibility. The majority (64%) of patients who could be reached via 
phone were screened for eligibility, and 94% of consenting patients were randomized to one 
of the study conditions. Additionally, retention was high with 83% of randomized patients 
completing the 8-week follow-up. Some evidence of preliminary efficacy also was obtained. 
When examining within-group change relative to baseline, the ACT group showed small to 
moderate decreases in fatigue interference and sleep-related impairment (d range = −.23 to 
−.31) at 8 and 12-week follow-ups, whereas the education/support group showed very 
minimal change in these outcomes. Furthermore, at 12-week follow-up, the ACT group 
showed moderate reductions in the severity of fatigue and sleep disturbance (both ds = −.
43), whereas the education/support group showed only small reductions in these outcomes 
(ds = −.24 and −.18 for fatigue and sleep disturbance, respectively). Differences between 
study conditions were not statistically significant; however, because this is a pilot study, we 
focused on effect sizes rather than statistical significance, especially given group imbalances 
in primary outcomes at baseline. To date, the few psychotherapy trials for MBC patients 
with fatigue and sleep outcomes have not shown evidence of efficacy [14,15]. As all patients 
in the current trial had one or more clinically meaningful symptoms at screening, changes in 
symptom outcomes following a brief intervention are noteworthy and suggest that ACT 
warrants further investigation in this understudied population.
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Although ACT has not been applied to physical symptom outcomes in cancer populations, 
this intervention has led to reduced fatigue in general population samples [41,42]. For 
example, an ACT trial targeting depressive symptoms in adults found that fatigue improved 
at 3-month follow-up relative to a waitlist control condition [41]. Furthermore, results of 
pilot studies suggest that interventions with similar components to ACT, such as 
mindfulness-based stress reduction (MBSR), may reduce fatigue interference and severity in 
post-treatment cancer survivors with persistent fatigue [43,44]. Mindfulness is a core 
element of ACT and may be a mechanism by which the intervention leads to reduced 
perceptions of symptom severity and interference [20]. For example, taking a non-
judgmental stance towards symptoms during mindfulness practice may interrupt maladaptive 
reactions to them, such as rumination. Furthermore, ACT’s emphasis on life values rather 
than symptom control may lead to more adaptive behaviors in service of stated values [20]. 
For instance, a patient may no longer avoid valued social activities when fatigued and may 
find that fatigue is less disruptive than previously perceived.
Both the ACT and education/support groups showed small decreases in depressive 
symptoms (ds = −.27 and −.28) and anxiety (ds = −.18 and −.08) between baseline and 12-
week follow-up. A minority of patients in this study had high levels of depressive symptoms 
and anxiety at baseline, which limited room for improvement during the intervention period. 
In addition, the primary goal of ACT is not distress reduction, but rather living a full, 
meaningful life despite distress and other symptoms [16]. Nevertheless, ACT has resulted in 
reduced distress in a few pilot studies with cancer patients [25], and meta-analytic evidence 
suggests that ACT is an efficacious treatment for distress in patients with chronic pain [23]. 
In this study, education regarding quality-of-life issues and supportive listening resulted in 
reductions in depressive symptoms comparable to those in the ACT condition. This finding 
aligns with meta-analytic evidence suggesting that psychoeducation has significant short-
term effects on distress in cancer patients [45].
Other outcomes in this study showed minimal change. On average, patients reported low 
levels of pain at baseline; thus, changes in pain interference and severity were small 
throughout the study period. Regarding global symptom interference, the ACT group 
showed small decreases (ds = −.19 and −.14), whereas the education/support group showed 
small increases (ds = .11 and .20) at 8 and 12-week follow-ups. The measure of global 
symptom interference referred to the degree to which “symptoms” interfered with mood and 
activities during the past 24 hours [34]. Thus, the lack of reference to specific symptoms and 
short time frame may have limited the measure’s sensitivity to change in symptom 
interference.
Several research directions may build upon the present findings. First, enrolling MBC 
patients with a specific symptom that interferes with activities, rather than patients with a 
range of symptoms, may increase the likelihood of detecting change in the primary outcome. 
Additionally, the degree to which ACT and education/support confer benefits beyond usual 
care warrants investigation in a 3-arm trial. Finally, holding more intervention sessions may 
bolster the effect size and expanding this work to different intervention modalities (e.g., 
video-conferencing) may further enhance its reach and effectiveness.
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Limitations of this study should be noted. About one-third of approached patients refused 
study participation, with the primary reason being lack of interest. The relatively small 
sample size limited statistical power for detecting effects and may have contributed to group 
imbalances on key outcomes at baseline, despite randomization. Thus, although we 
controlled for group differences at baseline, the ACT group had greater room for 
improvement on key outcomes. In addition, this study did not include follow-up assessments 
beyond 12 weeks post-baseline. Given that ACT involves the gradual development of skills, 
greater change in key outcomes may have been evidenced during a longer follow-up period. 
Finally, the sample consisted of primarily Caucasian and college-educated patients from a 
single institution in the midwestern United States. The extent to which findings generalize to 
diverse MBC patients warrants study.
In conclusion, this study supports the feasibility of a brief telephone-based ACT intervention 
for symptom interference in MBC patients. Preliminary effect size estimates suggest that 
ACT deserves further study, especially with respect to fatigue and sleep-related outcomes in 
this population. Given the high symptom burden in MBC patients [2–8] and the paucity of 
efficacious interventions to address their needs [14,15], developing and testing interventions 
to improve their symptom-related outcomes should be a high priority for future research.
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Fig. 1. 
Study CONSORT diagram
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Fig. 2. 
Changes in primary outcomes by study group
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Table 1
Summary of Topics Covered in Each Intervention Condition
Acceptance and Commitment Therapy Education/Support
• Discussion of current coping strategies for managing 
symptoms and suffering related to attempts to control 
symptoms and distress
• Experiential practice of mindfulness during sessions and at 
home (e.g., noticing one’s breath, noticing an object/scene)
• Practice with cognitive defusion--strategies to notice thoughts 
rather than being caught up in thoughts (e.g., passengers on the 
bus metaphor)
• Cultivating a transcendent sense of self--a perspective from 
which to observe and accept all changing experiences (e.g., tell 
oneself “I’m noticing I’m having that thought/emotion/
sensation”)
• Identifying core values (e.g., being an involved and loving 
parent, contributing at work)
• Identifying and practicing value-based actions, despite 
symptoms and distress
• Orientation to the cancer center and treatment 
team, overview of quality of life issues, and 
discussion of physical quality of life
• Discussion of social quality of life and referral 
to resources
• Discussion of other aspects of quality of life 
(emotional and cognitive functioning and roles 
and activities) and referral to resources
• Resources for managing financial challenges
• Tips for evaluating health information in books, 
magazines, and websites
• Review of prior sessions and referral to 
websites with cancer-related information
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Table 2
Patient Characteristics and Group Comparisons at Baseline
Characteristics
ACT
(n = 23)
Education/ Support
(n = 24)
t-test/ Fisher’s
Exact Test p
Age 0.08
  Mean 59.30 53.29
  SD 11.95 10.93
  Range 27 – 75 32 – 71
Race, n (%) 0.19
  Non-Hispanic white 19 (82.61) 23 (95.83)
Employment status, n (%) 0.13
  Employed full or part-time 6 (26.09) 7 (29.17)
  Retired 10 (43.48) 4 (16.67)
  Unemployed 7 (30.43) 13 (54.17)
Household income, n (%) 0.93
  $0 – $50,999 7 (30.43) 8 (33.33)
  $51,000 – $99,999 9 (39.13) 8 (33.33)
  $100,000 or more 6 (26.09) 8 (33.33)
  Missing 1 (4.35) 0 (0.00)
Years of education 0.68
  Mean (SD) 14.26 (2.09) 14.54 (2.55)
  Range 12 – 20 10 – 18
Married/living with a partner, n (%) 17 (73.91) 15 (62.50) 0.53
Psychiatric medication, n (%)a 12 (52.17) 13 (54.17) 1.00
Psychotherapy/counseling, n (%)a 1 (4.35) 3 (12.50) 0.61
Years since diagnosis 0.59
  Mean (SD) 4.87 (4.42) 4.25 (3.47)
  Range 0.51 – 16.35 0.23 – 15.85
Treatments received, n (%)
  Mastectomy 13 (56.52) 13 (54.17) 1.00
  Lumpectomy 8 (34.78) 7 (29.17) 0.76
  Chemotherapy 19 (82.61) 19 (79.17) 1.00
  Radiation 20 (86.96) 11 (45.83) 0.01
  Hormonal therapy 16 (69.57) 21 (87.50) 0.17
  Targeted therapy 11 (47.83) 15 (62.50) 0.39
Patient ECOG score at screening 0.68
  Mean (SD) 1.13 (0.69) 1.04 (0.75)
  Range 0 – 2 0 – 2
Global symptom interference at baseline 0.03
  Mean (SD) 4.01 (2.14) 2.69 (1.85)
  Range 1.17 – 8.83 0.00 – 6.83
Pain interference at baseline 0.44
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Characteristics
ACT
(n = 23)
Education/ Support
(n = 24)
t-test/ Fisher’s
Exact Test p
  Mean (SD) 9.13 (4.44) 8.17 (3.93)
  Range 4.00 – 20.00 4.00 – 17.00
Fatigue interference at baseline 0.04
  Mean (SD) 3.95 (2.34) 2.71 (1.71)
  Range 0.00 – 8.57 0.00 – 6.86
Sleep-related impairment at baseline 0.04
  Mean (SD) 23.04 (7.42) 18.79 (6.35)
  Range 9.00 – 40.00 10.00 – 32.00
Pain at baseline 0.82
  Mean (SD) 6.87 (2.78) 7.04 (2.20)
  Range 3.00 – 14.00 3.00 – 11.00
Fatigue at baseline 0.20
  Mean (SD) 13.43 (3.42) 12.04 (3.86)
  Range 7.00 – 20.00 4.00 – 17.00
Sleep disturbance at baseline 0.03
  Mean (SD) 13.39 (3.24) 11.50 (2.67)
  Range 7.00 – 18.00 6.00 – 16.00
Depressive symptoms at baseline 0.25
  Mean (SD) 8.04 (2.93) 7.00 (3.15)
  Range 4.00 – 14.00 4.00 – 15.00
Anxiety at baseline 0.42
  Mean (SD) 8.17 (2.99) 7.46 (3.02)
  Range 5.00 – 14.00 4.00 – 14.00
ACT = Acceptance and Commitment Therapy; SD = standard deviation; ECOG = Eastern Cooperative Oncology Group.
a
Patient reported receiving treatment in the past month at baseline.
Support Care Cancer. Author manuscript; available in PMC 2019 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mosher et al. Page 19
Table 3
Intent-to-Treat Results for Mixed-Effects Models Predicting Outcomes (N = 47)
Outcome Fixed Effect β SE P
Primary Outcomes:
Global symptom interference
  Baseline 0.77 0.13 <0.0001
  Group −0.31 0.52 0.55
  Time 0.11 0.27 0.68
Pain interference
  Baseline 0.75 0.11 <0.0001
  Group 0.64 0.92 0.49
  Time 0.28 0.32 0.39
Fatigue interference
  Baseline 0.80 0.11 <0.0001
  Group −0.06 0.44 0.89
  Time −0.05 0.21 0.82
Sleep-related impairment
  Baseline   0.73 0.10 <0.0001
  Group −0.74 1.35 0.59
  Time −0.11 0.72 0.88
Exploratory Outcomes:
Pain
  Baseline 0.69 0.12 <0.0001
  Group −0.02 0.58 0.97
  Time 0.43 0.17 0.01
Fatigue
  Baseline 0.70 0.10 <0.0001
  Group −0.32 0.74 0.67
  Time −0.32 0.41 0.44
Sleep disturbance
  Baseline   0.59 0.13 <0.0001
  Group   0.42 0.79 0.60
  Time −0.49 0.33 0.14
Depressive symptoms
  Baseline   0.65 0.10 <0.0001
  Group −0.04 0.62 0.94
  Time −0.21 0.26 0.42
Anxiety
  Baseline 0.46 0.10 <0.0001
  Group 0.05 0.61 0.93
  Time −0.02 0.28 0.94
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SE = standard error. For group effects, the education/support group is treated as the reference. For time effects, the first follow-up (8 weeks post-
baseline) is treated as the reference.
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